{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:21:52Z","timestamp":1793830912653,"version":"4.6.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40265-025-02195-9","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T09:37:32Z","timestamp":1748079452000},"page":"931-943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A Clinical Pharmacological Perspective on Intraperitoneal Chemotherapy"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6039-8458","authenticated-orcid":false,"given":"Pascale C. S.","family":"Rietveld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels A. D.","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan D. T.","family":"Sassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C. P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L. W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"2195_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.12.008","volume":"181","author":"A Rijken","year":"2023","unstructured":"Rijken A, van Erning FN, Rovers KP, Lemmens V, de Hingh I. On the origin of peritoneal metastases. Eur J Cancer. 2023;181:1\u20132.","journal-title":"Eur J Cancer"},{"issue":"2","key":"2195_CR2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1515\/pp-2017-0010","volume":"2","author":"E de Bree","year":"2017","unstructured":"de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum. 2017;2(2):47\u201362.","journal-title":"Pleura Peritoneum"},{"issue":"2","key":"2195_CR3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-022-01828-7","volume":"83","author":"NAD Guchelaar","year":"2023","unstructured":"Guchelaar NAD, Noordman BJ, Koolen SLW, Mostert B, Madsen EVE, Burger JWA, et al. Intraperitoneal chemotherapy for unresectable peritoneal surface malignancies. Drugs. 2023;83(2):159\u201380.","journal-title":"Drugs"},{"issue":"1","key":"2195_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34\u201343. https:\/\/doi.org\/10.1056\/NEJMoa052985. (PMID: 16394300).","journal-title":"N Engl J Med"},{"issue":"11","key":"2195_CR5","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/bjs\/znad228","volume":"110","author":"RAG van Eerden","year":"2023","unstructured":"van Eerden RAG, de Boer NL, van Kooten JP, Bakkers C, Dietz MV, Creemers GM, et al. Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases. Br J Surg. 2023;110(11):1502\u201310.","journal-title":"Br J Surg"},{"issue":"2","key":"2195_CR6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Quenet","year":"2021","unstructured":"Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2195_CR7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340.","journal-title":"N Engl J Med"},{"issue":"1","key":"2195_CR8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4251\/wjgo.v2.i1.19","volume":"2","author":"PH Sugarbaker","year":"2010","unstructured":"Sugarbaker PH, Van der Speeten K, Stuart OA. Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastrointest Oncol. 2010;2(1):19\u201330.","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"2195_CR9","doi-asserted-by":"crossref","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","volume":"288","author":"MF Flessner","year":"2005","unstructured":"Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol. 2005;288(3):F433\u201342.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"19","key":"2195_CR10","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36(19):1922\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2195_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","volume":"89","author":"RL Dedrick","year":"1997","unstructured":"Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst. 1997;89(7):480\u20137. https:\/\/doi.org\/10.1093\/jnci\/89.7.480.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2195_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/jcm12010103","volume":"12","author":"K Ren","year":"2022","unstructured":"Ren K, Xie X, Min T, et al. Development of the peritoneal metastasis: a review of back-grounds, mechanisms, treatments and prospects. J Clin Med. 2022;12(1):103. https:\/\/doi.org\/10.3390\/jcm12010103.","journal-title":"J Clin Med"},{"issue":"7","key":"2195_CR13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/jso.21702","volume":"102","author":"K Van der Speeten","year":"2010","unstructured":"Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. Pharmacology of perioperative 5-fluorouracil. J Surg Oncol. 2010;102(7):730\u20135.","journal-title":"J Surg Oncol"},{"issue":"2","key":"2195_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000011847","volume":"55","author":"P Jacquet","year":"1998","unstructured":"Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55(2):130\u20138. https:\/\/doi.org\/10.1159\/000011847.","journal-title":"Oncology"},{"issue":"4","key":"2195_CR15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejso.2007.05.007","volume":"34","author":"MT Seymour","year":"2008","unstructured":"Seymour MT, Trigonis I, Finan PJ, Halstead F, Dunham R, Wilson G, et al. A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer. Eur J Surg Oncol. 2008;34(4):403\u20139.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"2195_CR16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00280-014-2525-6","volume":"74","author":"Q Chalret du Rieu","year":"2014","unstructured":"Chalret du Rieu Q, White-Koning M, Picaud L, Lochon I, Marsili S, Gladieff L, et al. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia. Cancer Chemother Pharmacol. 2014;74(3):571\u201382.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2195_CR17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","volume":"13","author":"D Elias","year":"2002","unstructured":"Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13(2):267\u201372.","journal-title":"Ann Oncol"},{"issue":"4","key":"2195_CR18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000066229","volume":"63","author":"D Elias","year":"2002","unstructured":"Elias D, El Otmany A, Bonnay M, Paci A, Ducreux M, Antoun S, et al. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology. 2002;63(4):346\u201352.","journal-title":"Oncology"},{"issue":"10","key":"2195_CR19","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/annonc\/mdh398","volume":"15","author":"D Elias","year":"2004","unstructured":"Elias D, Matsuhisa T, Sideris L, Liberale G, Drouard-Troalen L, Raynard B, et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol. 2004;15(10):1558\u201365.","journal-title":"Ann Oncol"},{"issue":"4","key":"2195_CR20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00280-007-0654-x","volume":"62","author":"G Ferron","year":"2008","unstructured":"Ferron G, Dattez S, Gladieff L, Delord JP, Pierre S, Lafont T, et al. Pharmacokinetics of heated intraperitoneal oxaliplatin. Cancer Chemother Pharmacol. 2008;62(4):679\u201383.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2195_CR21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00280-012-2060-2","volume":"71","author":"C Perez-Ruixo","year":"2013","unstructured":"Perez-Ruixo C, Valenzuela B, Peris JE, Bretcha-Boix P, Escudero-Ortiz V, Farre-Alegre J, Perez-Ruixo JJ. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery. Cancer Chemother Pharmacol. 2013;71(3):693\u2013704.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2195_CR22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00280-020-04107-y","volume":"86","author":"LAW de Jong","year":"2020","unstructured":"de Jong LAW, Elekonawo FMK, Lambert M, de Gooyer JM, Verheul HMW, Burger DM, et al. Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study. Cancer Chemother Pharmacol. 2020;86(1):141\u201350.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2195_CR23","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00280-014-2436-6","volume":"73","author":"C Perez-Ruixo","year":"2014","unstructured":"Perez-Ruixo C, Peris JE, Escudero-Ortiz V, Bretcha-Boix P, Farre-Alegre J, Perez-Ruixo JJ, Valenzuela B. Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients. Cancer Chemother Pharmacol. 2014;73(5):1009\u201320.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2195_CR24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2020.09.010","volume":"140","author":"F Dumont","year":"2020","unstructured":"Dumont F, Passot C, Raoul JL, Kepenekian V, Lelievre B, Boisdron-Celle M, et al. A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers. Eur J Cancer. 2020;140:37\u201344.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2195_CR25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1245\/s10434-020-08743-9","volume":"28","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Tajzai R, Rovers KP, Wassenaar ECE, Moes DAR, Pluimakers G, et al. Systemic pharmacokinetics of oxaliplatin after intraperitoneal administration by electrostatic pressurized intraperitoneal aerosol chemotherapy (ePIPAC) in patients with unresectable colorectal peritoneal metastases in the CRC-PIPAC trial. Ann Surg Oncol. 2021;28(1):265\u201372.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"2195_CR26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijc.29011","volume":"136","author":"O Zivanovic","year":"2015","unstructured":"Zivanovic O, Abramian A, Kullmann M, Fuhrmann C, Coch C, Hoeller T, et al. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer. 2015;136(3):699\u2013708.","journal-title":"Int J Cancer"},{"issue":"1","key":"2195_CR27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/0091270009360980","volume":"51","author":"E Cotte","year":"2011","unstructured":"Cotte E, Colomban O, Guitton J, Tranchand B, Bakrin N, Gilly FN, et al. Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure. J Clin Pharmacol. 2011;51(1):9\u201318.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"2195_CR28","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/01.cad.0000176505.94175.d4","volume":"16","author":"B Royer","year":"2005","unstructured":"Royer B, Guardiola E, Polycarpe E, et al. Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anticancer Drugs. 2005;16(9):1009\u201316. https:\/\/doi.org\/10.1097\/01.cad.0000176505.94175.d4.","journal-title":"Anticancer Drugs"},{"issue":"3","key":"2195_CR29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00280-007-0484-x","volume":"61","author":"B Royer","year":"2008","unstructured":"Royer B, Delroeux D, Guardiola E, Combe M, Hoizey G, Montange D, et al. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. Cancer Chemother Pharmacol. 2008;61(3):415\u201321.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2195_CR30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejso.2019.06.022","volume":"47","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Azmi N, Fumagalli L, Baratti D, Guaglio M, Cavalleri A, et al. Phase II randomized study on tissue distribution and pharmacokinetics of cisplatin according to different levels of intra-abdominal pressure (IAP) during HIPEC (NCT02949791). Eur J Surg Oncol. 2021;47(1):82\u20138.","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"2195_CR31","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/bjc.1996.296","volume":"73","author":"JH Schellens","year":"1996","unstructured":"Schellens JH, Ma J, Planting AS, et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer. 1996;73(12):1569\u201375. https:\/\/doi.org\/10.1038\/bjc.1996.296.","journal-title":"Br J Cancer"},{"issue":"3","key":"2195_CR32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00280-023-04512-z","volume":"91","author":"LAW de Jong","year":"2023","unstructured":"de Jong LAW, Lambert M, van Erp NP, de Vries L, Chatelut E, Ottevanger PB. Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer Chemother Pharmacol. 2023;91(3):247\u201356.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2195_CR33","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0360-3016(93)90550-f","volume":"27","author":"KA Leopold","year":"1993","unstructured":"Leopold KA, Oleson JR, Clarke-Pearson D, et al. Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma. Int J Radiat Oncol Biol Phys. 1993;27(5):1245\u201351. https:\/\/doi.org\/10.1016\/0360-3016(93)90550-f.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2195_CR34","doi-asserted-by":"crossref","first-page":"20200137","DOI":"10.1515\/pp-2020-0137","volume":"5","author":"MS Mikkelsen","year":"2020","unstructured":"Mikkelsen MS, Blaakaer J, Petersen LK, Schleiss LG, Iversen LH. Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer. Pleura Peritoneum. 2020;5(4):20200137.","journal-title":"Pleura Peritoneum"},{"issue":"2","key":"2195_CR35","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2017.03.013","volume":"145","author":"DA Jandial","year":"2017","unstructured":"Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, et al. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: an NRG Oncology\/Gynecologic Oncology Group study. Gynecol Oncol. 2017;145(2):236\u201342.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2195_CR36","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ygyno.2005.06.055","volume":"99","author":"Y Miyagi","year":"2005","unstructured":"Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin\u2014a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol. 2005;99(3):591\u20136.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2195_CR37","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00280-015-2737-4","volume":"75","author":"SK Williamson","year":"2015","unstructured":"Williamson SK, Johnson GA, Maulhardt HA, Moore KM, McMeekin DS, Schulz TK, et al. A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax(R)) in patients with peritoneal malignancies. Cancer Chemother Pharmacol. 2015;75(5):1075\u201387.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2195_CR38","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1245\/s10434-007-9792-y","volume":"15","author":"E de Bree","year":"2008","unstructured":"de Bree E, Rosing H, Filis D, Romanos J, Melisssourgaki M, Daskalakis M, et al. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol. 2008;15(4):1183\u201392.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2195_CR39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/jso.22065","volume":"105","author":"M Imano","year":"2012","unstructured":"Imano M, Imamoto H, Itoh T, Satou T, Peng YF, Yasuda A, et al. Safety of intraperitoneal administration of paclitaxel after gastrectomy with en-bloc D2 lymph node dissection. J Surg Oncol. 2012;105(1):43\u20137.","journal-title":"J Surg Oncol"},{"issue":"3","key":"2195_CR40","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1006\/gyno.2002.6665","volume":"85","author":"LS Hofstra","year":"2002","unstructured":"Hofstra LS, Bos AM, de Vries EG, van der Zee AG, Willemsen AT, Rosing H, et al. Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer. Gynecol Oncol. 2002;85(3):517\u201323.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"2195_CR41","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a gynecoloic oncology group study. J Clin Oncol. 1992;10(9):1485\u201391. https:\/\/doi.org\/10.1200\/JCO.1992.10.9.1485.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2195_CR42","doi-asserted-by":"publisher","first-page":"e35566","DOI":"10.1002\/cncr.35566","volume":"131","author":"B Badgwell","year":"2025","unstructured":"Badgwell B, Ikoma N, Blum M, Wang X, Estrella J, Liu X, et al. Phase 1 trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology.\u00a0Cancer. 2025;131(1):e35566. https:\/\/doi.org\/10.1002\/cncr.35566.","journal-title":"Cancer"},{"issue":"3","key":"2195_CR43","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00280-012-2066-9","volume":"71","author":"H Tamegai","year":"2013","unstructured":"Tamegai H, Kaiga T, Kochi M, Fujii M, Kanamori N, Mihara Y, et al. Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites. Cancer Chemother Pharmacol. 2013;71(3):727\u201331.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2195_CR44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/ijgc-2018-000055","volume":"29","author":"SE Taylor","year":"2019","unstructured":"Taylor SE, Petschauer JS, Donovan H, Schorzman A, Razo J, Zamboni WC, et al. Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer. Int J Gynecol Cancer. 2019;29(1):147\u201352.","journal-title":"Int J Gynecol Cancer"},{"issue":"16 Pt 1","key":"2195_CR45","first-page":"5896","volume":"9","author":"RJ Morgan Jr","year":"2003","unstructured":"Morgan RJ Jr, Doroshow JH, Synold T, et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res. 2003;9(16 Pt 1):5896\u2013901.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2195_CR46","first-page":"1305","volume":"19","author":"S Fushida","year":"2008","unstructured":"Fushida S, Kinoshita J, Yagi Y, et al. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Oncol Rep. 2008;19(5):1305\u201310.","journal-title":"Oncol Rep"},{"issue":"6","key":"2195_CR47","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/psp4.13136","volume":"13","author":"PCS Rietveld","year":"2024","unstructured":"Rietveld PCS, Sassen SDT, Guchelaar NAD, et al. Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin. CPT Pharmacometrics Syst Pharmacol. 2024;13(6):1006\u201316. https:\/\/doi.org\/10.1002\/psp4.13136.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"2195_CR48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00280-010-1272-6","volume":"67","author":"MK Choi","year":"2011","unstructured":"Choi MK, Ahn BJ, Yim DS, Park YS, Kim S, Sohn TS, et al. Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding. Cancer Chemother Pharmacol. 2011;67(1):5\u201311.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2195_CR49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00280-010-1460-4","volume":"68","author":"K Van der Speeten","year":"2011","unstructured":"Van der Speeten K, Stuart OA, Chang D, Mahteme H, Sugarbaker PH. Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2011;68(1):147\u201356.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2195_CR50","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1179\/joc.2005.17.6.668","volume":"17","author":"D Cerretani","year":"2005","unstructured":"Cerretani D, Nencini C, Urso R, Giorgi G, Marrelli D, De Stefano A, et al. Pharmacokinetics of mitomycin C after resection of peritoneal carcinomatosis and intraperitoneal chemohyperthermic perfusion. J Chemother. 2005;17(6):668\u201373.","journal-title":"J Chemother"},{"issue":"2","key":"2195_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2165\/00003088-200443020-00005","volume":"43","author":"S van Ruth","year":"2004","unstructured":"van Ruth S, Math\u00f4t RA, Sparidans RW, Beijnen JH, Verwaal VJ, Zoetmulder FA. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clin Pharmacokinet. 2004;43(2):131\u201343. https:\/\/doi.org\/10.2165\/00003088-200443020-00005.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"2195_CR52","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00280-019-03767-9","volume":"83","author":"MC Cristea","year":"2019","unstructured":"Cristea MC, Frankel P, Synold T, Rivkin S, Lim D, Chung V, et al. A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Chemother Pharmacol. 2019;83(3):589\u201398.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2195_CR53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104151","volume":"82","author":"W Ceelen","year":"2022","unstructured":"Ceelen W, Sandra L, de Sande LV, Graversen M, Mortensen MB, Vermeulen A, et al. Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases. EBioMedicine. 2022;82: 104151.","journal-title":"EBioMedicine"},{"issue":"2","key":"2195_CR54","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1245\/s10434-022-12723-6","volume":"30","author":"M Choi","year":"2023","unstructured":"Choi M, Harper MM, Pandalai PK, Abdel-Misih SRZ, Patel RA, Ellis CS, et al. A multicenter phase 1 trial evaluating nanoliposomal irinotecan for heated intraperitoneal chemotherapy combined with cytoreductive surgery for patients with peritoneal surface disease. Ann Surg Oncol. 2023;30(2):804\u201313.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"2195_CR55","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1124\/dmd.112.047480","volume":"40","author":"E Salvatorelli","year":"2012","unstructured":"Salvatorelli E, De Tursi M, Menna P, Carella C, Massari R, Colasante A, et al. Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis. Drug Metab Dispos. 2012;40(12):2365\u201373.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"2195_CR56","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejso.2019.03.035","volume":"47","author":"PH Sugarbaker","year":"2021","unstructured":"Sugarbaker PH, Stuart OA. Pharmacokinetics of the intraperitoneal nanoparticle pegylated liposomal doxorubicin in patients with peritoneal metastases. Eur J Surg Oncol. 2021;47(1):108\u201314.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"2195_CR57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bcp.13773","volume":"85","author":"LAW de Jong","year":"2019","unstructured":"de Jong LAW, Elekonawo FMK, de Reuver PR, Bremers AJA, de Wilt JHW, Jansman FGA, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure. Br J Clin Pharmacol. 2019;85(1):47\u201358.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2195_CR58","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00280-003-0626-8","volume":"52","author":"VV de Lima","year":"2003","unstructured":"de Lima VV, Stuart OA, Mohamed F, Sugarbaker PH. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol. 2003;52(2):108\u201312.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2195_CR59","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.soc.2018.02.003","volume":"27","author":"N Lagast","year":"2018","unstructured":"Lagast N, Carlier C, Ceelen WP. Pharmacokinetics and tissue transport of intraperitoneal chemotherapy. Surg Oncol Clin N Am. 2018;27(3):477\u201394.","journal-title":"Surg Oncol Clin N Am"},{"key":"2195_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116820","volume":"176","author":"PCS Rietveld","year":"2024","unstructured":"Rietveld PCS, Guchelaar NAD, van Eerden RAG, et al. Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases. Biomed Pharmacother. 2024;176: 116820. https:\/\/doi.org\/10.1016\/j.biopha.2024.116820.","journal-title":"Biomed Pharmacother"},{"key":"2195_CR61","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.2025.43.4_suppl.327","volume":"43","author":"C Yan","year":"2025","unstructured":"Yan C, et al. Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: Results from the multicenter, randomized, phase 3 DRAGON-01 trial.\u00a0J Clin Oncol. 2025;43:327.\u00a0https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.327.","journal-title":"J Clin Oncol"},{"key":"2195_CR62","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev-med-081117-043436","volume":"70","author":"AE Russo","year":"2019","unstructured":"Russo AE, Strong VE. Gastric cancer etiology and management in Asia and the West. Annu Rev Med. 2019;70:353\u201367.","journal-title":"Annu Rev Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02195-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02195-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02195-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:55:28Z","timestamp":1750679728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02195-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":62,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2195"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02195-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"23 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Pascale C.S. Rietveld, Niels A.D. Guchelaar, Sebastiaan D.T. Sassen, Birgit C.P. Koch, Ron H.J. Mathijssen, and Stijn L.W. Koolen declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Pascale C.S. Rietveld: conceptualization, investigation, writing\u2014original draft, writing\u2014review and editing, and visualization. Niels A.D. Guchelaar: investigation and writing\u2014review and editing. Sebastiaan D.T. Sassen: supervision and writing\u2014review and editing. Birgit C.P. Koch: supervision and writing\u2014review and editing. Ron H.J. Mathijssen: writing\u2014review and editing and supervision. Stijn L.W. Koolen: conceptualization, investigation, writing\u2014review and editing, and supervision.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}